ClinicalTrials.Veeva

Menu

Identification of Biomarkers to Predict Driver Take-over Control Quality (ANTIDOTE)

P

PSA Automobiles

Status

Completed

Conditions

Healthy Subjects
Attention Deficit

Treatments

Behavioral: Driving simulator sessions

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT04188626
XP THSE BDX SNPSY
ID-RCB (ANSM number) (Other Identifier)

Details and patient eligibility

About

At level 3 conditionally automated, the vehicle ensures driving and the driver disengages from driving to perform another activity independent of driving (ex: read a book, play on his phone ....). However, drivers are expected to be available to take over control for the case of system failure or limitation. This take-over control must take place in a limited time, very short, of the order of a few seconds. To take-over control of the vehicle quickly and efficiently, the driver must be, at the time of take-over, vigilant, efficient, and attentive to the environment and focused on the take-over of manual driving. Predicting the driver's reengagement capabilities to ensure that the driver will be able to take-over control of the vehicle is crucial at level 3 of autonomous driving.

The objective of ANTIDOTE is to determine physiological and behavioural parameters capable of predicting the take-over quality in level 3 conditionally automated vehicles in a simulated highway driving situation in healthy drivers or drivers with attention disorders.

Full description

At level 3 conditionally automated, the vehicle ensures driving and the driver disengages from driving to perform non-related driving tasks (ex: read a book, play on his phone ....). However, drivers are expected to be available to take over control for the case of system failure or limitation. This take-over control must take place in a limited time, very short, of the order of a few seconds. To take-over control of the vehicle quickly and efficiently, the driver must be, at the time of take-over, vigilant, efficient, and attentive to the environment and focused on the take-over of manual driving. Predicting the driver's reengagement capabilities to ensure that the driver will be able to take-over control of the vehicle is crucial at level 3 of autonomous driving.

In this context, the objective of ANTIDOTE is to determine physiological and behavioural parameters capable of predicting the take-over quality in level 3 conditionally automated vehicles in a simulated highway driving situation.

This study will examine how engagement will impact take-over control quality in 6 non-driving related secondary tasks. A driving simulator study will be conducted and data from a total of 32 healthy drivers and 16 drivers with attention disorders will be used to evaluate take-over quality.

Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioral data will be recorded before, during and after the take-over control.

Enrollment

32 patients

Sex

All

Ages

20 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Common inclusion criteria:

  • male or female aged between 20 and 75 years old
  • BMI between 18 and 27
  • Subject size between 1.50 m and 1.95 m
  • Without sleep complains (Item of Basic Nordic Sleep Questionnaire ≤ 3)
  • Without excessive daytime sleepiness (Epworth score ≤ 11)
  • Non-professional drivers
  • Subjects with a driver's license for at least one year
  • Subjects driving at least 5000 km per year.
  • Having normal visual acuity (correction with lenses accepted) and normal color vision
  • Affiliated to a national health service
  • Having given written informed consent to participate in the trial.

Healthy volunteers specific inclusion criteria:

  • SCL90R score < 60 for anxiety and depression subscales
  • MMSE ≥ 30

ADHD patients specific inclusion criteria:

  • Patients with an ADHD disorder according to DSM 5,
  • Patients agreeing to discontinue psychostimulant treatment 48 hours prior to the experimental session,

Exclusion criteria

  • Severe life-threatening conditions in the short term,
  • Unstable endocrine diseases
  • Progressive cardiovascular diseases
  • Progressive neurological diseases treated or not,
  • Addiction to a substance
  • Night and shift-workers who has taken a constraints in the last 72 hours,
  • Psychotropic medication taking
  • Benzodiazepine or Z-drug medication taking
  • Cardiotropic medication taking
  • Volunteers who need glasses to drive
  • Having simulator-sickness during the first practice session

Healthy volunteers specific inclusion criteria:

  • Psychiatric co-morbidities: current major depressive episode, current hypomanic or manic episode, psychotic disorders, autism spectrum disorder
  • Exceeded consumption of coffee, tea or caffeinated drinks(> 5 cups / day)
  • Exceeded consumption of alcohol drinks (> 2 drinks / day during the last 6 months)

ADHD patients specific inclusion criteria:

  • Psychiatric co-morbidities: current major depressive episode, current hypomanic or manic episode, psychotic disorders, autism spectrum disorder (except ADHD)
  • Exceeded consumption of alcohol drinks(> 3 drinks / day during the last 6 months)

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

32 participants in 1 patient group

Driving session
Experimental group
Description:
The volunteers will be placed in a driving simulator that will simulate autonomous highway driving.
Treatment:
Behavioral: Driving simulator sessions

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems